Sagimet Biosciences Inc. Class A SGMT

Sagimet Biosciences (SGMT) priced an offering of about 8.8 million shares of series A common stock a

FOSTER CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the pricing of an underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per share, or for certain investors that so choose, in lieu of shares of Series A common stock, pre-funded warrants to purchase 2,750,010 shares of

In the Phase 3 open-label extension clinical trial (OLE), patients with moderate to severe acne received denifanstat for up to 52 weeks, including prior placebo patientsDenifanstat showed progressive and sustained improvements across all efficacy endpoints in the OLE, including Investigator's Global Assessment (IGA) success with a response rate of 57%, 72% reduction in total lesions, and 77% reduction in inflammatory lesions, and was generally well-tolerated, with no adverse event-related perman

The acne vulgaris market is expected to progress steadily, supported by an increasing number of emerging therapies advancing through clinical development. Key players, including Ascletis Pharma and Sagimet Biosciences with Denifanstat (ASC40), and AOB Pharma with B244, are demonstrating a strong commitment to addressing unmet needs in acne treatment through continued efforts to develop innovative therapeutic options.New York, USA, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Acne Vulgaris Market Set for S

FOSTER CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, September 30, 2026, at 1:00 PM ET featuring Julie Harper, MD, Founding Director and past President of the American Acne and Rosacea Society. To register, click here. Dr. Harper will jo

On August 11, Sagimet Biosciences Inc. (NASDAQ:SGMT) reported financial results for the quarter ended June 30, 2026. Research and development expense rose to $11.5 million from $7.2 million a year earlier as the company prepared for its Phase 3 trial, while general and administrative expense declined slightly to $4.3 million. Net loss widened to $14.0 […]

FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences. Cantor 2026 Global Healthcare Conference in New York, NY on Wednesday, September 9, 2026, with a fireside chat at 1.35pm ET (link here).H.C. Wainwright 28th Annual Global Investment Conf

All clinical trial sites identified and CRO retained Patient screening expected to begin in October 2026, with first patient to be enrolled shortly after FOSTER CITY, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that its AURORA Phase 3 clinical trial of FASN inhibitor denifanstat in moderate to severe acne is on tr

FOSTER CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in connection with the hiring of 3 employees, the Compensation Committee of Sagimet’s Board of Directors approved that an inducement grant of 260,700 stock options in aggregate to purchase shares of the Company’s Series A common stock be granted on Aug